Ascletis Pharma (HKSE:01672) Accounts Payable & Accrued Expense : HK$67.86 Mil (As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Ascletis Pharma Accounts Payable & Accrued Expense?

Ascletis Pharma's quarterly accounts payable & accrued expense declined from Dec. 2023 (HK$108.69 Mil) to Jun. 2024 (HK$46.67 Mil) but then increased from Jun. 2024 (HK$46.67 Mil) to Dec. 2024 (HK$67.86 Mil).

Ascletis Pharma's annual accounts payable & accrued expense increased from Dec. 2022 (HK$79.85 Mil) to Dec. 2023 (HK$108.69 Mil) but then declined from Dec. 2023 (HK$108.69 Mil) to Dec. 2024 (HK$67.86 Mil).

Ascletis Pharma Accounts Payable & Accrued Expense Historical Data

The historical data trend for Ascletis Pharma's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ascletis Pharma Accounts Payable & Accrued Expense Chart

Ascletis Pharma Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

68.13

76.47

79.85

108.69

67.86

Ascletis Pharma Semi-Annual Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial												79.85	87.29	108.69	46.67	67.86

Ascletis Pharma Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Ascletis Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ascletis Pharma Inc (HKSE:01672) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

ASCLF:USA 2VJ:Germany

Address

198 Qidi Road, 12th Floor, Building D, HIPARK, Xiaoshan District, Zhejiang Province, Hangzhou, CHN, 311200

Website

https://www.ascletis.com

Ascletis Pharma Inc is an investment holding company. Along with its subsidiaries, it is engaged in the research and development, production, marketing, and sale of pharmaceutical products. It has three marketed products, i.e. Ritonavir tablets, GANOVO, and ASCLEVIR. It also has other drug candidates in its pipeline in their different stages of development such as ASC22, ASC10, ASC11, and ASC40 among others. Geographically, it operates in Mainland China and other regions.

Executives

Wu Jinzi Jason	2101 Beneficial owner
Wu Judy Hejingdao	2101 Beneficial owner
Jjw12 Limited
Lakemont Holding Llc
Jjw11 Limited
C-bridge Capital Gp, Ltd.	2201 Interest of corporation controlled by you
Fu Wei	2201 Interest of corporation controlled by you
Tf Capital Ii Ltd.	2201 Interest of corporation controlled by you
Tf Capital, Ltd.	2201 Interest of corporation controlled by you
Kang Hua Investment Company Limited	2201 Interest of corporation controlled by you
Yang Dan	2201 Interest of corporation controlled by you

Ascletis Pharma Headlines

No Headlines